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Abstract
Background: Bordetella pertussis causes whooping cough or pertussis in humans. It produces
several virulence factors, of which the fimbriae are considered adhesins and elicit immune
responses in the host. B. pertussis has three distinct serotypes Fim2, Fim3 or Fim2,3. Generally, B.
pertussis Fim2 strains predominate in unvaccinated populations, whereas Fim3 strains are often
isolated in vaccinated populations. In Finland, pertussis vaccination was introduced in 1952. The
whole-cell vaccine contained two strains, 18530 (Fim3) since 1962 and strain 1772 (Fim2,3) added
in 1976. After that the vaccine has remained the same until 2005 when the whole-cell vaccine was
replaced by the acellular vaccine containing pertussis toxin and filamentous hemagglutinin. Our aims
were to study serotypes of Finnish B. pertussis isolates from 1974 to 2006 in a population with >
90% vaccination coverage and fimbrial expression of the isolates during infection. Serotyping was
done by agglutination and serotype-specific antibody responses were determined by blocking
ELISA.
Results: Altogether, 1,109 isolates were serotyped. Before 1976, serotype distributions of Fim2,
Fim3 and Fim2,3 were 67%, 19% and 10%, respectively. From 1976 to 1998, 94% of the isolates
were Fim2 serotype. Since 1999, the frequency of Fim3 strains started to increase and reached 83%
during a nationwide epidemic in 2003. A significant increase in level of serum IgG antibodies against
purified fimbriae was observed between paired sera of 37 patients. The patients infected by Fim3
strains had antibodies which blocked the binding of monoclonal antibodies to Fim3 but not to Fim2.
Moreover, about one third of the Fim2 strain infected patients developed antibodies capable of
blocking of binding of both anti-Fim2 and Fim3 monoclonal antibodies.
Conclusion: Despite extensive vaccinations in Finland, B. pertussis Fim2 strains were the most
common serotype. Emergence of Fim3 strains started in 1999 and coincided with nationwide
epidemics. Results of serotype-specific antibody responses suggest that Fim2 strains could express
Fim3 during infection, showing a difference in fimbrial expression between in vivo and in vitro.
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Background
Bordetella pertussis, the causative agent of whooping cough
or pertussis produces several virulence factors during the
course of infection, including adhesins, toxins and
lipopolysaccharide [1]. Fimbriae are long, filamentous
appendages reaching out from the outer membrane of the
bacterium. Structurally they consist of two proteins, major
and minor subunit, the latter of which is considered an
adhesin [1]. Even though the in vivo mechanism by which
the fimbriae interact with the host is not fully understood,
it is evident that fimbriae elicit protective immune
responses and therefore are included in some acellular
pertussis vaccines [2-4].
Expression of fimbriae is regulated at two levels: as part of
Bordetella virulence gene (bvg)-locus and as an individual
gene through phase variation [1,5]. By this form of pheno-
typic variation where the changes are heritable as well as
reversible, bacteria gain increased persistence in the host
environment [5]. In B. pertussis the level of expression of
the two phase-variable major subunits of fimbriae, Fim2
and Fim3, determines the serotype which can therefore be
either Fim2, Fim3 or Fim2,3. A homopolymeric tract of
cytosine is located at the promoter region of fim-genes,
and a small deletion or insertion of C's there can cause the
phase transition between the high and low level of expres-
sion [6]. Serotyping has been an essential part of charac-
terizing B. pertussis clinical isolates for a long time [7] and
studies on strain variation have shown that B. pertussis
populations are dynamic and continuously evolving
[8,9].
Generally, vaccination has been shown to induce a shift in
Fim expression of the strains in a way that in unvaccinated
populations Fim2 strains are predominant, while they are
largely displaced by Fim3 strains when vaccination is
introduced with a whole cell vaccine containing both
Fim2 and Fim3 [10-13]. In Finland, whole-cell vaccine
has been used since 1952. From 1962 vaccine consisted of
the serotype Fim3 strain 18530. Because of the predomi-
nance of the Fim2 strains in the country, the serotype
Fim2,3 strain 1772 was added. The vaccine with equal
amounts of two strains remained the same until 2005
when the whole cell vaccine was replaced by the acellular
vaccine containing only pertussis toxin (Ptx) and filamen-
tous hemagglutinin. The vaccine coverage of four doses
has been > 90%.
In the present study, we compared serotypes of B. pertussis
strains circulating in Finland over time. A large number of
clinical isolates from 1974 to 2006 were available for the
analysis. We also investigated the antibody responses to B.
pertussis fimbrial antigens during infection and serotype-
specific antibody responses by a newly developed block-
ing ELISA.
Results
Serotype of B. pertussis isolates
From 1974 to 2006, 1,109 isolates were collected and
serotyped (Figure 1). In 1974 and 1975, serotype distribu-
tions of Fim2, Fim3 and Fim2,3 were 67% (number of
Fim2/total number, 28/42), 19% (8/42) and 10% (4/42),
respectively. From 1976 to 1998, 94% (667/710) of the
isolates were Fim2. Two nationwide epidemics occurred
in Finland in 1999 and 2003–2004. In 1999, the fre-
quency of Fim3 started to increase and reached 83% (77/
93) in 2003, the highest observed during the study period.
The frequency of Fim2,3 strains has remained low
throughout the whole period (Figure 1).
Anti-pertussis IgG antibodies
Serum samples from 41 patients with culture-confirmed
pertussis were available for studying of antibody
responses to Ptx and purified Fim2/3 mixture. There were
37 paired and 4 single sera. Serotype distributions of the
corresponding isolates were 85% for Fim2, 10% for Fim3,
and 5% for Fim2,3.
From 37 patients for whom diagnosis was confirmed by
culture, paired serum samples were available. Most of the
paired serum samples were taken at the early (defined as
< 3 weeks of cough) and at the late stage (defined as ≥ 3
weeks of cough) of infection. The mean of interval
between the paired sera was 32 days (range, 12–56 days).
The levels of anti-Fim and anti-Ptx-IgG antibodies were
determined. A significant increase between the paired sera
was found in the levels of IgG antibodies to Ptx [28.7 ±
29.3 ELISA units (EU) vs 53.1 ± 22.5 EU] and Fim2/3 mix-
ture (30.4 ± 23.4 EU vs 75.0 ± 18.9 EU) (p < 0.001 for
both antigens). For the 4 single sera, IgG antibodies to Ptx
were 19.7, 121.7, 64,3 and 9.1 EU and IgG antibodies to
Fim2/3 mixture 72,2, 62,7, 37.0 and 28.7 EU.
Serotype distributions of B. pertussis isolates in Finland from  1974 to 2006 Figure 1
Serotype distributions of B. pertussis isolates in Fin-
land from 1974 to 2006. A total of 1,109 isolates were 
collected and serotyped.
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IgG antibodies were also determined in 60 single serum
samples of patients with serologically diagnosed pertussis
in 2004. The mean level of IgG antibodies was 79,1 (CV%
= 21) for Ptx and 66,0 (CV% = 30,6) for Fim2/3, a level
similar to that obtained from second serum samples of
patients with culture-confirmed pertussis.
As a negative control, paired serum samples from 10 ran-
domly selected vaccine recipients who received one
booster dose of a three-component acellular pertussis vac-
cine not including fimbriae were analyzed. No change in
the levels of anti-Fim2/3 IgG antibodies was found
between the paired sera, whereas a significant increase in
anti-Ptx IgG levels were observed 30 days after the vacci-
nation (p < 0.005).
Detection of epitope-specific antibody responses to 
fimbriae
The blocking assay was developed for the detection of
epitope-specific antibodies against the fimbriae. Because
there are no purified Fim 2 and Fim3 antigens available
separately, it is not possible to differentiate antibodies to
Fim2 from those to Fim3 by conventional ELISA. In this
blocking assay antibodies formed against Fim2 or Fim3
are detected as they block the binding of monoclonal anti-
bodies to Fim2 or Fim3 antigen, which in this case are
Fim2 and Fim3 expressing B. pertussis strains. The block-
ing assay has been previously used for the detection of
antibodies against pertactin [14].
First we studied the specific binding of the monoclonal
antibodies, designated mAbFim2 and mAbFim3 to the
two types of coating antigens: purified Fim2/3 mixture
and Fim2- or Fim3-expressing B. pertussis strains S1(Fim2)
and S3(Fim3). Specific binding of monoclonal antibodies
to Fim2- or Fim3-expressing B. pertussis strains as well as
to Fim2/3 mixture was observed.
Next we examined if there was difference in the blocking
of binding of mAbFim2 and mAbFim3 to the two types of
coating antigens by human antibodies. Because the block-
ing of binding of mAbFim2 and mAbFim3 to coating anti-
gens was only observed in presence of serum anti-Fim
antibodies and the blocking effect seemed to be dose-
dependent (see below), ten serum samples were ran-
domly selected from the serum samples of 41 patients
with culture-confirmed pertussis and tested. Although the
blocking of binding of mAb to coating antigens was
observed, no difference was found in the level of blocking
of binding of mAbFim2 and mAbFim3 to the two types of
coating antigens (data not shown). The Fim2- and Fim3-
expressing strains were eventually chosen as coating anti-
gens for the study because of limited amount of purified
Fim2/3 mixture.
In presence of serum from patient infected with Fim2
strains, blocking of binding of mAbFim2 to S1(Fim2) was
observed (Figure 2, left panel), whereas blocking of bind-
ing of mAbFim2 to S1(Fim2) was not changed in presence
of serum from patient infected with Fim3 strains. In Fig-
ure 2, patients 48I and 10II were infected by Fim2 strains
Blocking of binding of mAbFim2 and mAbFim3 to Fim2-expressing strain S1 (left) and of mAbFim3 and mAbFim2 to Fim3- expressing strain S3 (right) by human IgG antibodies to fimbriae Figure 2
Blocking of binding of mAbFim2 and mAbFim3 to Fim2-expressing strain S1 (left) and of mAbFim3 and 
mAbFim2 to Fim3-expressing strain S3 (right) by human IgG antibodies to fimbriae. Patients 48I and 10II were 
infected by Fim2 strains and patient 2026 by Fim3 strain. Blocking of binding of mAbFim2 and mAbFim3 to S1 and S3 by normal 
sheep serum in PBS (NSS-PBS) was not observed. Data were from a single experiment. Three sera with different blocking lev-
els were tested twice and the results obtained were same. In each experiment, both positive and negative controls were 
included, and all the experiments were performed by an experienced technician.BMC Microbiology 2008, 8:162 http://www.biomedcentral.com/1471-2180/8/162
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and patient 2026 by Fim3 strain. The level of blocking of
binding of mAbFim2 to S1(Fim2) was 54%, 81% and 6%,
respectively (Figure 2, left panel). Blocking of binding of
mAbFim2 and mAbFim3 to S1(Fim2) and S3(Fim3) by
normal sheep serum in PBS (NSS-PBS) was not observed.
In presence of serum from patient infected with Fim3
strain, blocking of binding of mAbFim3 to S3(Fim3) was
observed (Figure 2, right panel). However, in presence of
sera from some of patients infected with Fim2 strains,
blocking of binding of mAbFim3 to S3(Fim3) was also
found, indicating the presence of anti-Fim3 antibodies in
the patients infected with Fim2 strains. The level of block-
ing of binding of mAbFim3 to S3(Fim3) was 81%, 26%
and 74% for patients 48I, 10II and 2026, respectively (Fig-
ure 2, left panel).
No cross-reaction between mAbFim3 and S1(Fim2) or
mAbFim2 and S3(FIm3) was observed, no matter in pres-
ence or absence of patient serum (Figure 2). Two dilutions
(1:10 and 1:100) of serum samples were tested. Blocking
of binding of mAbs to Fim2 or Fim3 expressing strains
was increased relative to increasing serum concentration,
showing that the blocking effect is dose-dependent.
Blocking levels of sera from patients with culture-confirmed pertussis
Altogether 41 serum samples from culture-confirmed
patients of which 37 had paired samples were investigated
for development of specific antibodies against Fim2 and
Fim3 during infection. Of the 37 patients with paired sera,
34 were infected by Fim2 strains, two by Fim2,3 strains
and one by Fim3 strain. In addition, three single serum
samples were obtained from Fim3 infected patients.
All four patients infected with Fim3 strains had high levels
of blocking of binding of mAbFim3 to S3(Fim3) (range,
66% to 74% and median, 70%), whereas the blocking lev-
els of mAbFim2 to S1(Fim2) were marginal (range, 3% to
15% and median 8%). Two patients infected with Fim2,3
strains had high levels of blocking of binding of both anti-
bodies, 57% and 56% for mAbFim2 to S1(Fim2) and
80% and 89% for mAbFim3 to S3(Fim3) in their second
sera.
The range of serum blocking level of mAbFim2 to
S1(Fim2) in the first sera of Fim2-infected patients was
from 0% to 62% (median, 11%) and in second sera from
9% to 93% (median, 51%). The difference between paired
sera was statistically significant (p < 0.0001). The blocking
levels of mAbFim3 to S3(Fim3) were also tested for Fim2-
infected patients. Thirty-four Fim2-infected patients were
divided into three groups according to level of IgG anti-
bodies to Fim2/3 mixture and blocking levels of
mAbFim2 to S1(Fim2) and mAbFim3 to Fim3(S3)
between the paired sera.
Group 1 included 12 patients who had significant
increases in level of IgG antibodies to Fim2/3 mixture and
in blocking level of mAbFim2 to S1(Fim2) between
paired sera (p < 0.01) but had no change in blocking level
of mAbFim3 to S3(Fim3) (Figure 3).
Group 2 consisted of 11 patients who had significant
increases in level of IgG antibodies to Fim2/3 mixture and
in blocking levels of both mAbFim2 to S1(Fim2) and
mAbFim3 to S3(Fim3) between paired sera (p < 0.01 for
both) (Figure 3).
Group 3 included 11 patients who had no change either
in level of IgG antibodies to Fim2/3 mixture or in block-
ing levels of both mAbFim2 to S1(Fim2) and mAbFim3 to
S3(Fim3) between paired sera (Figure 3).
Of the 34 Fim2-infected patients, 11 patients had already
had high level of the blocking (≥ 40%) of mAbFim3 to
S3(Fim3) in the first sera, and in 9 of them the blocking
level remained high in the second sera. Of the 11 patients,
3 were in group 1, 2 in group 2, and 6 in group 3 (Figure
3). Taken together, the patients who were infected with
Fim2 strains, can also produce anti-Fim3 antibodies
which indicate that Fim2 strains may express Fim3 during
the course of infection.
Blocking levels of sera from patients with serologically confirmed 
pertussis
Of the 34 patients who were infected by Fim2 strains and
had paired sera (see above), 23 (Groups 1 and 2) had sig-
nificant increases in level of IgG antibodies to Fim2/3
mixture and in blocking level of mAbFim2 to S1(Fim2)
(Figure 3). All the 23 patients had blocking level of
mAbFim2 to S1(Fim2) ≤ 30% in their first sera (Figure 3).
Of the four patients infected by Fim3 strains, one had
paired sera and three had only single sera. All four patients
had blocking level of binding of mAbFim3 to S3(Fim3) >
50%. Therefore, 40% was empirically determined as cut-
off level and considered significant.
In 60 sera of patients with serologically diagnosed pertus-
sis in 2004, the range of blocking level was 0% to 86.4%
(median, 23.1%) for mAbFim2 to S1(Fim2) and 7.4% to
91.7% (median, 63.9%) for mAbFim3 to S3(Fim3). In 42
sera the blocking level of mAbFim3 to S3(Fim3) was con-
sidered significant (≥ 40%), whereas in 16 sera the block-
ing level of mAbFim2 to S1(Fim2) was significant. In five
sera the significant blocking levels were detected for both
mAbFim2 to S1(Fim2) and mAbFim3 to S3(Fim3).
Since no blocking of mAbFim2 to S1(Fim2) was detected
in sera of culture-confirmed patients infected by Fim3
strains (see above section), the five patients who had sig-
nificant blocking for both seemed to be infected by Fim2BMC Microbiology 2008, 8:162 http://www.biomedcentral.com/1471-2180/8/162
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or Fim2,3 strains. If this is the case, 37 (62%) of 60
patients would have been infected by Fim3 strains. In Fin-
land, a nationwide epidemic occurred in 2003 to 2004.
During this period, the serotype distributions of Fim2,
Fim3 and Fim2,3 were 32%, 66% and 1%, respectively,
when 231 B. pertussis isolates were collected and tested.
Discussion
In this study, we present the epidemiology of different
serotypes of B. pertussis strains circulating in Finland
where the vaccination against pertussis has been used
since early 1950s. Results are based on an analysis of a
large number of isolates collected over time covering four
decades. In addition, we investigated human antibody
responses to B. pertussis fimbrial antigens during infection
and serotype-specific antibodies by a newly developed
blocking ELISA. Our data suggest that Fim2 strains can
express both Fim2 and Fim3 during infection, showing a
difference in fimbrial expression between in vitro and in
vivo. To our knowledge, this is the first study that shows
that B. pertussis serotype detected in vitro may not reflect its
expression in vivo.
Detection of epitope-specific antibody responses to fimbriae in paired sera from Fim2 infected patients Figure 3
Detection of epitope-specific antibody responses to fimbriae in paired sera from Fim2 infected patients. Group 
1 included 12 patients who had significant increases in level of IgG antibodies to fimbriae and in blocking level of mAbFim2 to 
S1(Fim2) between paired sera (p < 0.01) but had no change in blocking level of mAbFim3 to S3. Group 2 consisted of 11 
patients who had significant increases in level of IgG antibodies to fimbriae and in blocking levels of both mAbFim2 to S1(Fim2) 
and mAbFim3 to S3(Fim3) between paired sera (p < 0.01 for both). Group 3 included 11 patients who had no change either in 
level of IgG antibodies to fimbriae or in blocking levels of both mAbFim2 to S1(Fim2) and mAbFim3 to S3(Fim3) between 
paired sera.
Group 1 Group 2 Group 3BMC Microbiology 2008, 8:162 http://www.biomedcentral.com/1471-2180/8/162
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Many studies have shown that Fim2 isolates predominate
in unvaccinated populations, while they are largely dis-
placed by Fim3 strains when vaccination is introduced
with a whole cell vaccine containing both Fim2 and Fim3
[10-13]. In Sweden, before 1979 when the whole-cell vac-
cine was used, 70% of circulating strains were Fim3 [11].
From 1979 to 1995 when the pertussis vaccination was
stopped, Fim2 started to increase and reached 64% in
early 1990s. In 1996 when general vaccination with an
acellular vaccine was reintroduced, the prevalence of Fim2
declined and Fim3 strains emerged rapidly. In 2002 and
2003, serotype Fim3 constituted 96% among fully vacci-
nated individuals. In contrast to the high prevalence of
Fim3 strains in many countries with long-term vaccina-
tion, Fim2 has been the prevalent serotype in Finland for
more than 20 years. The Finnish whole cell vaccine con-
tains two strains expressing Fim3 and Fim2,3, and this
vaccine has remained the same since 1976. The exact rea-
sons for the dominance of serotype Fim2 strains in Fin-
land are not known. One explanation is that different
whole cell vaccines were used in different countries. The
exact amounts of Fim2 and Fim3 in these vaccines are
unknown, although all whole cell pertussis vaccines used
in the world contain both Fim2 and Fim3 as recom-
mended by WHO. Another explanation is that immunity
to Fim2 and Fim3 in Finnish population might not be the
same as in other populations. The population immunity
to fimbrial antigens comes from vaccination or natural
infection or both. We have previously compared clinical
isolates recovered since the early 1990s in Finland and
France, two countries with similar histories of long-term
mass vaccination with whole cell vaccines. In France, 90%
of isolates in 1990s were Fim3. Furthermore, although
isolates in both countries were genetically similar, they
varied temporally [15].
It is recommended that monoclonal antibodies are used
for serotyping of B. pertussis and that Fim2- and Fim3-
expressing reference strains are included as controls [10-
12]. The two mAbs used in the present study were pro-
duced from hybridoma cell lines BPF2 and BPC10 and
were proven to be specific for serotype Fim2 and serotype
Fim3 [16]. They are being used in many countries for sero-
typing. The same mAbs and reference strains were also
used in the blocking ELISA. No cross reaction was found
between mAbs and reference strains used as coating anti-
gens. Moreover, all patients who were infected with Fim3
strains had developed specific antibodies to Fim3 but not
to Fim2. The development of anti-Fim3 antibodies was
also observed in sera of patients with serologically diag-
nosed pertussis in 2004 when Fim3 strains were prevalent.
It is known that B. parapertussis also produces similar vir-
ulence factors including fimbriae. In Finland, infections
caused by B. parapertussis are detected in children 2 to 8
years of age [17]. Eight Finnish B. parapertussis strains iso-
lated during 1990s were randomly selected from our
strain collection and tested for agglutination with the two
mAbs used in the present study and no agglutination was
detected (data not shown). This indicates that there is no
cross reaction between the mAbs and B. parapertussis.
However, it remains to be studied if sera from parapertus-
sis patients can block the binding of the mAbs to Fim2- or
Fim3-expressing strains.
Fim 2 and 3 are similar in structure since they have an
NH2-terminal amino acid sequence homology of about
75% and have identical helical structures demonstrated
by electron microscopic analysis [18-20]. Moreover, the
two fimbriae were found to contain unique antigenic
epitopes, which is consistent with their being serotype-
specific agglutinogens [16]. In a previous report, Robin-
son and his colleagues showed that Fim2 and Fim3 are
generally not cross-reactive [21]. Although some cross-
reactivity was mentioned, the cross-reactive epitopes
could be non-protective epitopes. They also found that
immunization of mice with sero-specific agglutinogen
resulted in immune selection so that organisms recovered
following infection did not express the immunizing anti-
gen [21]. In this present study, 32% of patients who were
infected with Fim2 strains had developed IgG antibodies
which blocked the binding of anti-Fim3 monoclonal anti-
bodies to Fim3, indicating that the antibodies were
induced by Fim3 antigen. Therefore, in addition to expres-
sion of Fim2, the Fim2 strains might express Fim3 in vivo
during the interaction with host cells. Alternatively, these
patients might have been previously infected with a Fim3
strain. Upon subsequent infection with a Fim2 strain, not
only a new immune response to Fim2 specific epitopes
but also a boosting response to Fim2/3 cross-reactive
epitopes (that would be very close to those bound by the
mAbs) would be induced. It is interesting to study if there
is cross-reactive immune response induced by the two
fimbriae and if the cross-reactive immune response is pro-
tective or not. The expression of different fimbrial major
subunits is phase variable and is a consequence of inser-
tion or deletion of cytosines in C-rich region at the pro-
moter region of fim2 and fim3 genes [6]. Phase variation
is one means for the bacterium to create phenotypic diver-
gence and to avoid host defense mechanisms [5]. Fim-
briae have also shown some level of phase variation in vivo
[6,22]. Neisseria meningitidis has a phase-variable immu-
nogenic outer membrane protein, PorA, which has a con-
trol mechanism similar to Bordetella fimbriae. The length
of variable homopolymeric tracts at the promoter regions
of PorA showed variation between strains isolated from
carriers and strains isolated from patients [23].
Recently, the annotated genome sequence of B. pertussis
was published [24]. The genome contains 3,816 ORFs.BMC Microbiology 2008, 8:162 http://www.biomedcentral.com/1471-2180/8/162
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According to the sequenced genome, the genes encoding
Fim2 (BP1119) and Fim3 (BP1568) are located apart
from each other, suggesting that in certain circumstances
the regulation of expression of the two genes may be dif-
ferent. A recent study where microarray-based gene
expression profiling was used, reported differential mod-
ulation of B. pertussis virulence genes [25]. In the B. pertus-
sis strain, which represents serotype Fim2, the fim3 gene
was found to be expressed in virulence repressing condi-
tions, whereas fim2 was expressed in virulence activating
conditions and confirmed to be a virulence activated
gene. Another study has also confirmed that in B. pertussis
fim2 gene but not fim3 gene was Bvg-activated gene [26].
In vaccinated populations, symptoms of pertussis can be
mild and the patients do not usually seek for medical
help. Therefore the possibility that some of patients who
were infected by Fim2 strains may have already had infec-
tions caused by Fim3 strains, could not be excluded. How-
ever, the frequency of circulating Fim3 strains was very
low in Finland during the period when the sera were col-
lected. Also, according to the Finnish vaccination sched-
ule and the age of patients at the time of sampling, it is
unlikely that the anti-Fim3 antibodies detected in patients
who were infected by Fim2 strains were due to recent vac-
cinations.
In the present study, some patients who were infected by
Fim2 strains had already had anti-Fim3 antibodies in the
first sera (Figure 3), and in most of them levels of the anti-
bodies remained unchanged in the second sera. One
explanation might be that the first serum samples had
been taken when the patients were already at the convales-
cent phase or these patients had developed anti-Fim anti-
bodies exceptionally rapidly.
B. pertussis continues to cause epidemics in vaccinated
populations in spite of high vaccination coverage. As a
result of this study we gained more information of the
possible mechanisms the bacterium uses to infect highly
vaccinated populations. This information is important for
the future development of vaccines against pertussis.
Conclusion
Despite extensive vaccinations in Finland, Fim2 strains
were the most common serotype. Fim3 strains emerged
since 1999 and the emergence coincided with nationwide
epidemics. In a population with long-term vaccinations,
Fim2 strains could express Fim3 during infection, show-
ing a difference in fimbrial expression between in vivo and
in vitro.
Materials and methods
Bacterial strains, serum samples and study subjects
A total of 1,109 B. pertussis isolates were obtained from
1974 to 2006 and stored in strain collections of the
Department of Vaccine, National Public Health Institute,
Helsinki (from 1974 to 1994) and the Pertussis Reference
Laboratory, National Public Health Institute, Turku (from
1991 on). The number of isolates collected each year var-
ied from 4 to 138 and was 112 in 1974–1976, 182 in
1977–1979, 70 in 1980–1982, 70 in 1983–1985, 67 in
1986–1988, 81 in 1989–1991, 78 in 1992–1994, 78 in
1995–1997, 77 in 1998–2000, 121 in 2001–2003, 173 in
2004–2006. The isolates had been sent from the local
clinical microbiology laboratories or collected during the
outbreaks of pertussis.
Of the strains studied, 41 were isolated from patients from
whom serum samples were also available. The serum sam-
ples were collected at the Pertussis Reference Laboratory
of the National Public Health Institute, Turku, Finland.
No selection of the serum samples was done, because all
the patients from whom both sera and bacterial strains
were available were included. Of the 41 patients, 39 were
diagnosed in 1990s [27,28], one was in 2004 and one was
in 2005. Of the 23 patients whose vaccination status was
investigated, 19 had received four doses of Finnish diph-
theria-tetanus-whole cell pertussis vaccine and 4 had
received three doses of the same vaccine. None of the 41
patients had received acellular pertussis vaccine because
in Finland the acellular vaccine was introduced in January
2005. Age of the 41 patients ranged from 4 months to 64
years (mean, 17 years and median, 10 years). Of the
patients, 37 had paired sera and 4 single sera. The mean of
interval between the paired sera was 32 days (range, 12–
56 days). Of the 37 patients who had paired sera, 32 had
already cough at the first blood sampling, three developed
cough later and two remained asymptomatic [27,28].
Fim2 strains predominated in 1990s and Fim3 strains
started to increase since 1999. Because only two culture-
positive patients had sera available since 2000, 60 sera
from patients who were serologically diagnosed in 2004
at the Department of Medical Microbiology and Immu-
nology, University of Turku, Turku were included [29].
The selection criteria for the 60 patients were based on
diagnostic level of serum anti-Ptx IgG antibodies. Age of
the patients ranged from 1 to 47 years (mean, 17 years).
Only single sera were available from the patients.
In addition, paired serum samples from 10 vaccinees were
randomly selected to serve as negative controls for detec-
tion of antibody responses to fimbrial antigens. The vac-
cinees received one booster dose of acellular pertussis
vaccine containing Ptx, filamentous hemagglutinin and
pertactin but not fimbriae [30]. The serum samples wereBMC Microbiology 2008, 8:162 http://www.biomedcentral.com/1471-2180/8/162
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taken before and 30 days after the booster vaccination.
Age of the subjects ranged from 10 to 13 years.
Serotyping
Serotyping of B. pertussis strains was done by slide aggluti-
nation or indirect ELISA. The slide agglutination test was
performed as described previously [31]. In the indirect
ELISA method, validated by Tsang et al. [32] the microtiter
plate was coated overnight at room temperature with 100
μl of B. pertussis suspension, inactivated at 56°C for 1
hour, with OD 0,1 at 620 nm. Strains specifically express-
ing either Fim2(S1) or Fim3(S3), kindly provided by Dr.
D. Xing, National Institute for Biological Standards and
Control (NIBSC), UK, were included in each run as posi-
tive controls. Wells were washed with phosphate-buffered
saline (PBS) and blocked with 150 μl 1% normal sheep
serum (NSS) (Autogen Bioclear UK Ltd, Wiltshire, UK) in
PBS (NSS-PBS) at 37°C for 1 hour. After the blocking and
each following incubation step wells were washed three
times with 0,05% (w/v) NaCl, 0,05%Tween20 (Sigma,
St.Louis, USA) (v/v). Anti-Fim2 or anti-Fim3 monoclonal
antibodies (mAbFim2 or mAbFim3) diluted in PBS
(1:1000), produced and provided by NIBSC, UK were
added, and the plate was incubated at 37°C for 2 hours.
Anti-mouse antibodies (DakoCytomation, Glostrup,
Denmark) (1:2000 in NSS-PBS) were added, and the plate
was incubated at 37°C for 2 h. After the addition of phos-
phatase substrate (Sigma, Steinheim, Germany) in dieth-
anolamine-MgCl2-buffer (Reagena, Toivala, Finland),
absorbance at 405 nm was measured with Victor 1420
Multilabel counter (Wallac, Turku, Finland) consecutively
until the absorbance of control strains reached 1,5.
ELISA for determination of serum IgG antibody
For determination of serum IgG antibodies to Ptx and
purified Fim2/3 mixture microtiter plates were coated
with 1 μg/ml of purified Ptx or purified Fim2/3 mixture
for overnight at room temperature. Ptx was kindly pro-
vided by GlaxoSmithKline Biologicals, Rixensart, Bel-
gium. Fim2/3 mixture preparation (code 85/549) was
provided by NIBSC, UK and with purity of ≥ 95% of Fim
2/3 components by SDS-PAGE. Due to absence of stand-
ards for purified Fim 2 and Fim 3 antigen, the proportion
of each Fim2 and Fim3 in this mixture preparation has
not been defined. If assuming similar affinity for both
anti-Fim2 and Fim3 mAbs to the antigens, this prepara-
tion contains 10% higher amount of Fim 2 than Fim 3 by
in-house ELISAs. The detailed ELISA used in the present
study was described earlier [14,27]. Plates were washed
with 200 μl PBS and then incubated with 150 μl 1% NSS-
PBS at 37°C for 1 hour. Serum samples diluted 1:100
were added and incubated in duplicate wells at 37°C for
2 hours. After IgG conjugate diluted 1:800 (DakoCytoma-
tion) was incubated at 37°C for 2 hours, 100 μl of phos-
phatase substrate (Sigma) in diethanolamine-MgCl2-
buffer (Reagena) was added. Absorbance in 405 nm was
measured consecutively until the absorbance of positive
serum pool reached 1,5. The positive and negative pool
sera were included in each run, and results were expressed
as relative ELISA units (1 ELISA unit, 1:100 of the corre-
sponding antibody concentration in the positive pool
sera).
Blocking ELISA
Blocking ELISA [14] was used to test the ability of human
antibodies to compete with specific monoclonal antibod-
ies in binding to Fim2 or Fim3 expressing strains. The
mAbs used in blocking ELISA were the same as those for
serotyping. Microtiter plates were coated with 100 μl of
bacterial suspension of B. pertussis strains expressing either
Fim2 or Fim3 for overnight at room temperature (see sec-
tion of Serotyping). Plates were washed with 200 μl PBS,
pH 7, 2–7, 4 and incubated with 150 μl 1% NSS-PBS at
37°C for 1 hour and washed three times with 200 μl
0,05% NaCl, 0,05% Tween20 (Sigma). The NaCl-Tween
buffer was used for washings. One hundred microliter of
serum samples diluted 1:10 were added in duplicate wells
and were incubated at 37°C for 2 hours. NSS-PBS and
samples from negative and positive serum pool were used
as controls and included in each run. One hundred micro-
liter of mAbFim2 or mAbFim3 diluted 1:1000 in PBS were
added, and the plates were incubated at 37°C for 2 hours.
Anti-mouse conjugate (DakoCytomation) diluted 1:2000
in NSS-PBS was added and incubated at 37°C for 2 hours.
Finally, 100 μl of phospathase substrate (Sigma) in dieth-
anolamine-MgCl2-buffer (Reagena) was added. Absorb-
ance in 405 nm was measured consecutively until the
absorbance of NSS-PBS was reached to 1,5. The relative
blocking of binding of mAb to Fim2 or Fim3 was calcu-
lated as 100% – absorbance of testing serum/absorbance
of NSS-PBS. Blocking level of a serum ≥ 40% was consid-
ered significant.
Statistical analysis
Paired t-test was used for statistical analysis of the differ-
ences in level of antibodies and relative blocking of bind-
ing of mAb between paired serum samples. P value < 0,05
was considered significant.
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